ASCO 2025 – Day 4 Highlights (06/03/2025)

--**AMPLITUDE: Niraparib + AAP reduced rPFS risk by 37% vs. AAP alone in HRR-altered mCSPC—first study to show benefit in this setting.
 --NDMM: Elranatamab + Daratumumab + Lenalidomide showed high response rate in newly diagnosed multiple myeloma.
 --RRMM: Trispecific antibody showed high response rate in phase 1 trial for relapsed/refractory multiple myeloma.
 --RELATIVITY-098 (melanoma): Nivolumab + Relatlimab failed to improve RFS in resectable stage III/IV melanoma; one of my patients participated but couldn't tolerate it.
 --CAN-2409 (prostate cancer): In situ HSV-TK viral immunotherapy + valacyclovir triggered CD8+ T cell response with manageable toxicity—very innovative.
 --** Plenary – NIVOPOSTOP: Adjuvant nivolumab + CRT improved DFS in high-risk resected HNSCC (GORTEC 2018-01).
 --** Plenary – ATOMIC: Atezolizumab + chemo improved DFS in stage III dMMR colon cancer (Alliance A021502).
 --** Plenary Closing: Dr. Mark Andrew Lewis urged us to align data with patients' goals—living for a wedding, a grandchild, a dream. “When there’s a dream, pursue it now.”
 --** DeLLphi-304 (SCLC, 6/2): Tarlatamab improved OS (13.6 vs. 8.3 mo, HR 0.60) and PFS (4.2 vs. 3.7 mo, HR 0.71) vs. chemo in previously treated small cell lung cancer.